anti-CD19-glucosteroid receptor modulator ADC ABBV-31

An antibody drug conjugate (ADC) composed of an afucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the B-cell-specific membrane protein CD19 conjugated to a glucocorticoid receptor (GR) modulator (GRM), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19-GRM ADC ABBV-319 targets and binds to CD19. thereby inducing antibody-dependent cellular cytotoxicity (ADCC). Additionally, by delivering the GRM payload directly to CD19-expressing tumor cells, ABBV-319 inhibits the activation of GR-dependent expression of proliferative and anti-apoptotic genes. This induces apoptosis and inhibits tumor cell proliferation in CD19-expressing tumor cells. CD19 is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies and drives B-cell proliferation. GRMs show robust anti-tumor activity against B-cell malignancies.